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A B S T R A C T
The aim of this work was to evaluate the mucus-permeating properties of nanocarriers using zein nanoparticles
(NPZ) coated with a Gantrez® AN-thiamine conjugate (GT). NPZ were coated by incubation at diﬀerent GT-to-
zein ratios: 2.5% coating with GT (GT-NPZ1), 5% (GT-NPZ2) and 10% (GT-NPZ3). During the process, the GT
conjugate formed a polymer layer around the surface of zein nanoparticles. For GT-NPZ2, the thickness of this
corona was estimated between 15 and 20 nm. These nanocarriers displayed a more negative zeta potential than
uncoated NPZ. The diﬀusivity of nanoparticles was evaluated in pig intestinal mucus by multiple particle
tracking analysis. GT-NPZ2 displayed a 28-fold higher diﬀusion coeﬃcient within the mucus layer than NPZ
particles. These results align with in vivo biodistribution studies in which NPZ displayed a localisation restricted
to the mucus layer, whereas GT-NPZ2 were capable of reaching the intestinal epithelium. The gastro-intestinal
transit of mucoadhesive (NPZ) and mucus-permeating nanoparticles (GT-NPZ2) was also found to be diﬀerent.
Thus, mucoadhesive nanoparticles displayed a signiﬁcant accumulation in the stomach of animals, whereas
mucus-penetrating nanoparticles appeared to exit the stomach more rapidly to access the small intestine of
animals.
1. Introduction
In 1982, the Food and Drug Administration (FDA) approved the ﬁrst
commercially-available recombinant protein for the treatment of dia-
betic patients (Leader et al., 2008). Three decades after the approval of
recombinant insulin, more than 239 diﬀerent therapeutic proteins and
peptides have been approved for clinical use (Lau and Dunn, 2018;
Usmani et al., 2017). Peptides and proteins oﬀer a higher speciﬁcity
and potency as well as a lower interference with normal biological
processes than conventional small-molecule drugs (Mitragotri et al.,
2014; Skalko-Basnet, 2014). In general, all of these compounds are
administered as a parenteral injection. However, the inherent short
half-lives of these biomacromolecules require frequent administrations
that may compromise patient compliance and, thus, restrict their
therapeutic value, particularly for chronic diseases (Remington et al.,
2013; Shah et al., 2016).
In the last decades, enormous research eﬀorts have been devoted to
the development of formulation strategies for the oral delivery of these
compounds. The oral administration of proteins and peptides is
attractive for many patients due to the absence of pain and discomfort
associated to injections (Muheem et al., 2016). In addition, from a
technological point of view, the manufacture of oral medicines does not
require particular facilities, process or containers to produce and
maintain sterile conditions. In addition, for certain polypeptides, such
as insulin or indeed incretin mimetics such as exenatide, the oral de-
livery route is more closely mimics the physiological process (Fonte
et al., 2013). The oral delivery of proteins and peptides remains an
important challenge with many developmental issues to solve. The
physico-chemical properties (i.e., MW, hydrophilic character or pre-
sence of ionisable functional groups) and enzymatic sensitivity strongly
hamper the absorption of therapeutic proteins and peptides. As a con-
sequence, their oral bioavailability (in general) is really low (< 1%)
(Muheem et al., 2016; Yin et al., 2014).
In order to solve these drawbacks, the use of biodegradable nano-
particles has been proposed. In principle, these pharmaceutical dosage
forms may encapsulate the therapeutic compound and, thus, oﬀer
protection against its eventual hydrolytic or enzymatic degradation. In
addition, and due to their matrix structure, these nanoparticles may
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control the release of the cargo. However, in many cases, these devices
possess mucoadhesive properties and remain trapped in the protective
mucus layer covering the gut epithelium (Ensign et al., 2012; Lai et al.,
2009). In the particular case of protein and peptide delivery, this may
be an important limitation with greater exposure of any released
polypeptide to the digestive enzymes localized in the luminal space
adjacent to the glycocalyx covering the surface of enterocytes (Bruno
et al., 2013; Maher et al., 2016). In addition, mucoadhesive properties
of nanoparticles limits their residence time within the gut mucosa
which will be determined by the mucus turn-over (Dawson et al., 2004;
Lai et al., 2009). The use mucus-permeating nanocarrier has been
suggested as an alternative to minimize such issues.
In order to generate these devices, diﬀerent alternatives have been
proposed, including the use of immobilized proteolytic enzymes on the
surface of the nanocarriers (Pereira de Sousa et al., 2015), the co-en-
capsulation of mucolytic agents (Netsomboon and Bernkop-Schnürch,
2016), or the design of zeta potential changing systems (Perera et al.,
2015). Another possibility may be the use of “slippery” nanoparticles
which possess a highly-dense hydrophilic coat shielding hydrophobic
interactions between the nanoparticles and the components of the
mucus and facilitating passage through this mucus biopolymer. The
coating of nanoparticles with poly(ethylene glycol) (Inchaurraga et al.,
2015; Li et al., 2001) or surfactants such as Pluronic®F 127 (Schneider
et al., 2017) has also explored, as the use of surfactant- based micellar
drug delivery systems (Menzel et al., 2018).
In this context, the aim of this work was to develop and evaluate the
mucus-permeating properties of nanocarriers based on the coating of
zein nanoparticles with a Gantrez® AN-thiamine conjugate. Zein is a
Generally Recognised as Safe (GRAS) material that, due to its amphi-
philic character, can easily interact with a wide group of compounds,
including proteins (Cserháti and Forgács, 2005). Signiﬁcantly, nano-
particles based on the conjugate between Gantrez® AN and thiamine
have demonstrated the capability to reach the intestinal epithelium
minimizing their retention in the protective mucus gel layer
(Inchaurraga et al., 2019).
2. Materials and methods
2.1. Materials
The copolymer of methylvinylether and maleic anhydride or poly
(anhydride) (Gantrez® AN 119) was supplied by Ashland Inc.
(Barcelona, Spain). Thiamine hydrochloride, zein, mannitol, lysine,
agarose, glutaraldehyde, propylene oxide, sodium cacodylate and
EPON™ were purchased from Sigma-Aldrich (Madrid, Spain). Ethanol
were provided by Panreac (Barcelona, Spain). Acetone was obtained
from VWR-Prolabo, (Linars del Vallès, Spain). Perylene-Red (BASF
Lumogen® F Red 305) was from Kremer Pigmente GmbH & Co.
(Aichstetten, Germany) and OCT™ Compound Tissue-Tek from Sakura
Finetek Europe (Alphen aan Der Rijn, The Netherlands). 4′,6-diami-
dino-2-phenylindole (DAPI) was obtained from Biotium Inc. (Madrid,
Spain). Glass bottom imaging dishes (35mm diameter dish with a glass
coverslip at 1.5 mm thick and 10mm diameter) were from MatTek
Corporation (Ashland, USA). PLGA nanoparticles (PDLG-5002 con-
taining lactic:glycolic at 50%:50%, MW 17 KDa.) with a mean size of
161 ± 0.03 nm and a zeta potential of −29.2 ± 2.11, were supplied
by Nanomi B.V. (Oldenzaal, The Netherlands).
2.2. Mucus
Freshly isolated pig intestinal ileum (2m in length from proximal
region) was obtained from a local abattoir (Cardiﬀ, UK) and kept in ice-
cold oxygenated phosphate buﬀered saline (PBS) (no longer than 2 h)
prior to sample processing. The ileum was processed into 25 cm lengths
with each length incised longitudinally to allow intestinal food and
other waste debris to be was gently rinsed away by ice-cold PBS. The
mucus was then harvested using by an approach that optimized the
yield of the loose mucus layer but critically also a signiﬁcant amount of
the adherent mucus layer (Cone, 2009). The intestinal surface was
gently scraped by spatula which limits the shedding of intestinal epi-
thelial tissue. Mucus was divided into aliquots (0.5 g) and kept at
−20 °C prior to experimentation (Larhed et al., 1998).
2.3. Preparation of Gantrez® AN-thiamine conjugate (GT)
The conjugate was created by the covalent binding of thiamine to
the poly(anhydride) backbone (Inchaurraga et al., 2019). To achieve
this, 5 g Gantrez® AN were dissolved in 200mL acetone. Then, 125mg
thiamine was added and the mixture was heated at 50 °C, under mag-
netic agitation at 400 rpm, for 3 h. The mixture was ﬁltered through a
pleated ﬁlter paper and the organic solvent was eliminated under re-
duced pressure in a Büchi R-144 apparatus (BÜCHI Labortechnik AG,
Flawil, Switzerland). Finally, the resulting powder was stored at room
temperature. The conjugate was named GT.
2.4. Preparation of zein nanoparticles coated with the Gantrez® AN-
thiamine conjugate (GT-NPZ)
Zein nanoparticles were prepared by a desolvation procedure
(Peñalva et al., 2015) and then coated with the synthesized Gantrez®
AN-thiamine conjugate. The resulting nanoparticles were puriﬁed,
concentrated and, ﬁnally, dried. In brief, 200mg zein and 30mg lysine
were dissolved in 20mL ethanol 55% and incubated under agitation at
RT for 15min. In parallel, a 2% aqueous solution of the Gantrez® AN-
thiamine conjugate was prepared by dispersing the polymer in puriﬁed
water till complete solubilisation. Nanoparticles were obtained after the
addition of 20mL puriﬁed water to the hydroalcoholic solution of zein
and lysine. Then, a determined volume of GT solution (0.25, 0.5 or
1mL) was added and the mixture was maintained under agitation at RT
for 30min. The resulting suspension of nanoparticles was puriﬁed and
concentrated down to 20mL by ultraﬁltration through a polysulfone
membrane cartridge of 500 kDa pore size (Medica SPA, Medolla, Italy).
Finally, 10 mL of a mannitol aqueous solution (4% w/v) was added to
the suspension of nanoparticles and the mixture was dried in a Büchi
Mini Spray Drier B-290 apparatus (Büchi Labortechnik AG, Switzer-
land). The following parameters were selected: inlet temperature of
90 °C, outlet temperature of 60 °C, spray-ﬂow of 600 L/h, and aspirator
at 100% of the maximum capacity. The zein coated nanoparticles were
named as GT-NPZ.
As control, “naked” zein nanoparticles (NPZ) were prepared in the
same way as described above but in the absence of GT.
For diﬀerent in vitro and in vivo studies, ﬂuorescently labeled na-
noparticles were used. Here, 2.5mL of a 0.04% Lumogen®F red 305
solution in pure ethanol was added to the hydroalcoholic solution
containing zein and lysine. The mixture was maintained under agita-
tion. Then, the nanoparticles were prepared, puriﬁed and dried as de-
scribed above.
2.5. Preparation of poly(anhydride) nanoparticles (PA-NP)
Nanoparticles based on Gantrez®AN (PA-NP) were prepared as de-
scribed previously (Ojer et al., 2010) and employed as control of mu-
coadhesive nanoparticles. Brieﬂy, 400mg Gantrez® AN were dissolved
in 20mL acetone. The nanoparticles were formed by the addition of
40mL ethanol followed of the addition of 40mL puriﬁed water. The
organic solvents were eliminated under reduced pressure, puriﬁed by
centrifugation at 5000×g for 20min (SIGMA Lab. centrifuges, Osterode
am Harz, Germany) using dialysis tubes Vivaspin® 300,000 MWCO
(Sartorius AG, Madrid, Spain) and, ﬁnally dried by Spray-drying. The
nanoparticles displayed a size of 213 ± 2 nm and a zeta potential of
−53 ± 2mV.
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2.6. Characterization of nanoparticles
2.6.1. Particle size, zeta potential and yield
The particle size, polydispersity index (PDI) and zeta-potential were
determined by photon correlation sprectroscopy (PCS) and electro-
phoretic laser Doppler anemometry respectively, using a Zetasizer
analyser system (Brookhaven Instruments Corporation, New York,
USA). The diameter of the nanoparticles was determined after disper-
sion in ultrapure water (1/10) and measured at 25 °C by dynamic light
scattering angle of 90°. The zeta potential was determined as follows:
200 μL of the samples were diluted in 2mL of a 0.1mM KCl solution
adjusted to pH 7.4.
In order to quantify the amount of protein transformed into nano-
particles, 10mg of the nanoparticle formulation was dispersed in water
and centrifuged at 17.000×g for 20min. Supernatants were discarded
and the pellets were digested with ethanol 75%. Then, the amount of
protein was quantiﬁed by UV spectrophotometry at 278 nm in an
Agilent 8453 system (Agilent Technologies, USA). For analysis, cali-
bration curves were constructed between 90 and 1200 µg/mL
(R2 greater than 0.999; quantitation limit= 143 µg/mL). The amount
of protein forming nanoparticles in the formulation was estimated as
the ratio between the amount of the protein quantiﬁed in the pellet of
the centrifuged samples and the total amount of protein used for the
preparation of nanoparticles and expressed in percentage.
2.7. Morphology and shape
The morphology and shape of nanoparticles were evaluated by
TEM. In brief, 20mg of the spray dried powder containing the nano-
particles were dispersed in 2mL cacodylate 0.1M containing glutar-
aldehyde 4%. After one hour of incubation, nanoparticles were cen-
trifuged at 100×g (5min). The pellet was resuspended in 2mL water
and centrifuged again. Then, 2mL of osmium 1% was added to the
nanoparticles and kept at 4 °C for 1 h. The excess of osmium was
eliminated by centrifugation at 100×g for 5min. Nanoparticles were
resuspended in 2mL water and centrifuged again. Then, 200 µL of
agarose 2% were added to the nanoparticles, vortexed for 1min and
kept at 4 °C overnight. From this sample, 1 mL was inserted into an
embedding ﬂask and dehydrated with ethanol of increasing graduation
for 3 h. Then, gelatin capsules were ﬁlled with a solution of propylene
oxide-EPON™ (1:1) and the samples were inserted. These capsules were
incubated at increasing temperatures (37 °C, 45 °C and 60 °C) for the
polymerization of the EPON™. Finally, 50–70 nm sections of the sam-
ples were obtained with a Leica Ultracut R ultramicrotome (Wetzlar,
Germany). The sections were placed in a copper grid and treated with
3% uranil acetate-lead for 5min and completely dried at room tem-
perature. For the visualization of nanoparticles, a Zeiss Libra 120
Transmission Electron Microscope (Oberkochen, Germany) coupled
with a digital imaging system Gatan Ultrascan 1000 2 k×2 k CCD was
used.
2.8. Quantiﬁcation of Lumogen® F red 305
The amount of Lumogen®F Red 305 red loaded in the nanoparticles
was quantiﬁed by UV–Vis spectrometry at wavelength 580 nm
(Labsystems iEMS Reader MF, Vantaa, Finland). For this purpose, the
diﬀerence between its initial concentration added and the concentra-
tion found in the supernatant after the centrifugation of the samples in
water (2800×g for 20min) was calculated. For quantiﬁcation, standard
curves of Lumogen®F Red in ethanol 75% were used (concentration
range of 5–30 µg/mL; R2≥ 0.999).
2.9. Radiolabeling of nanoparticles with 99mTc
Nanoparticles were radiolabeled with technetium-99 m by reduc-
tion with stannous chloride as described (Areses et al., 2011). For this
purpose, 0.8–1.0 mg nanoparticles were pre-tinned with 0.05mg/mL of
SnCl2 and subsequently labelled for 30min with 1–2mCi of freshly
eluted 99mTc-pertechnetate from 99Mo-99mTc generator. The overall
procedure was carried out in helium-purged vials. The radiochemical
purity was analysed by radiochromatography (Whatman 3MM, NaCl
0.9%). The radiolabeling yield was always over 95%.
2.10. Multiple particle tracking (MPT) in mucus
The diﬀusion of nanoparticles through porcine intestinal mucus
barrier was assessed by MPT technique (Abdulkarim et al., 2015;
Rohrer et al., 2016). Samples (0.5 g) of porcine intestinal mucus were
incubated in glass-bottom MatTek imaging dishes at 37 °C. The ﬂuor-
escently labelled nanoparticles were inoculated into each 0.5 g mucus
sample in a 25 µL aliquot at a suspension concentration of 0.002%. To
ensure eﬀective particle distribution following inoculation within the
mucus, a 2 h period of equilibration was adopted prior the capture of
nanoparticle movements by video microscopy. Video capture involved
2-dimensional imaging on a Leica DM IRB wide-ﬁeld epiﬂuorescence
microscope (x63 magniﬁcation oil immersion lens) using a high speed
camera (Allied Vision Technologies, Stadtroda, Germany) running at a
frame rate of 33ms i.e. capturing 30 frames sec−1; each completed
video ﬁlm comprised 300 frames. For each 0.5 g mucus sample ap-
proximately 120 nanoparticles were simultaneously tracked and their
movements captured. Videos were imported into Fiji ImageJ software
to convert the movement of each nanoparticle into individual nano-
particles trajectories across the full duration of the 10 s videos. How-
ever, for the analysis of particle diﬀusion only a 30 frame video period
(1 s) was used, with the criterion that any individual particle tracked
must display a continuous presence in the X-Y plane 8 throughout the
respective 30 sequential frames. The individual particle trajectories
were converted into numeric pixel data (Mosaic Particle Tracker within
Fiji ImageJ) which, based on the microscope and video capture settings,
was converted into metric distance. The distances moved by every in-
dividual particle over a selected time interval (Δt) in the X-Y trajectory
were then expressed as a squared displacement (SD). The mean square
displacement (MSD) of any single particle (n) represents the geometric
mean of that particle’s squared displacements throughout its entire 30-
frame trajectory. MSD was determined as follows (Macierzanka et al.,
2014):
= +MSD (XΔt) (YΔt)n( ) 2 2 (1)
For each nanoparticle type studied an “ensemble mean square dis-
placement” (deﬁned by < MSD > ) was then determined for each of
the three replicate studies. The Eﬀective Diﬀusion Coeﬃcient
(<Deﬀ > ) for a particular nanoparticle type was then calculated by:
< > = < >Deff MSD t/ (4Δ ) (2)
where 4 is a constant relating to the 2-dimensional mode of video
capture and Δt is the selected time interval.
The proportion of diﬀusive particles through the mucus matrix was
evaluated by measuring particle diﬀusion across various time intervals
(Lai et al., 2009). Eq. (3) was used to determine a Diﬀusivity Factor
(DF) which expresses the eﬀective diﬀusion coeﬃcient for each in-
dividual particle (Deﬀ) across the time intervals (Δt) of 1 and 0.2 s,
when it is considered as Brownian motion.
= = =fDF Deff Δ t 1sec/Def Δ t 0.2 sec (3)
where the individual particle Deﬀ=MSD/(4Δt). Particles with a DF
value of 0.9 and greater were deﬁned as diﬀusive. The proportion of the
diﬀusive particles within a given NP type under study was then cal-
culated and expressed as %Diﬀusive particles.
In parallel, the particles’ diﬀusion coeﬃcient (D°) in water was
calculated by the Stokes-Einstein equation at 37 °C (Philibert, 2005).
For this purpose, Eq. (4) was applied:
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=
∘ κT πηrD /6 (4)
where k is Boltzmann constant, T is absolute temperature, η is water
viscosity and r is radius of the particle.
The diﬀusion of all particles was also expressed as the parameter, %
ratio [Deﬀ]/[D°] which provided a measure of the relative eﬃciency of
particle diﬀusion through mucus when particles’ intrinsic free
Brownian motion in water is taken into account. As such it aﬀords
comparison of particle diﬀusion in mucus after accounting for the im-
pact of a particles’ surface composition upon its unrestricted diﬀusion
in solution. It is essentially a measure that more directly addresses the
relative impact between particles of diﬀering surface physico-chemical
properties and the interactions, and the steric hindrance of the mucin
network.
2.11. Gastro-intestinal transit studies with 99mTc-nanoparticles
These studies were carried out in female Wistar rats weighing
250–300 g. All the procedures were performed following a protocol
previously approved by the “Ethical and Biosafety Committee for
Research on Animals” at the University of Navarra in line with the
European legislation on animal experiments.
Animals were lightly anaesthetised with 2% isoﬂurane gas for ad-
ministration of nanoparticles (dispersed in 1mL water) by oral gavage,
and then quickly awakened. Each animal received one single dose of
radiolabeled nanoparticles (1 mCi; 0.8–1.0mg radiolabeled nano-
particles that were completed with up to 10mg with unlabelled nano-
particles). SPECT/CT studies were performed three hours after admin-
istration of 99mTc-nanoparticles, animals were anaesthetised with 2%
isoﬂurane gas and placed in prone position on the gamma camera
(Symbia T2 Truepoint; Siemens Medical System, Malvern, USA). The
acquisition parameters for SPECT studies were: 128×128 matrix, 90
images, 7 images per second and CT: 110mAs and 130 Kv, 130 images,
slice thickness 3mm. Fused images were processed using the Syngo MI
Applications TrueD software.
2.12. Biodistribution studies with ﬂuorescently labeled nanoparticles
The tissue distribution of nanoparticles in the gastrointestinal mu-
cosa was visualized by ﬂuorescence microscopy. For that purpose,
25 mg of Lumogen® F Red-labeled nanoparticles were orally adminis-
tered to rats as described above. Two hours later, animals were sacri-
ﬁced by cervical dislocation and the guts were removed. Ileum portions
of 1 cm were collected, cleaned with PBS, stored in the tissue pro-
ceeding medium OCT™ and frozen at−80 °C. Each portion was then cut
into 5-µm sections on a cryostat and attached to glass slides. Finally,
these samples were ﬁxed with formaldehyde and incubated with DAPI
(4′,6-diamidino-2-phenylindole) for 15min before the cover assembly.
The presence of both ﬂuorescently loaded poly(anhydride) nano-
particles in the intestinal mucosa and the cell nuclei dyed with DAPI
were visualized in a ﬂuorescence microscope (Axioimager M1, Zeiss,
Oberkochen, Germany) with a coupled camera (Axiocam ICc3, Zeiss,
Oberkochen, Germany) and ﬂuorescent source (HBO 100, Zeiss,
Oberkochen, Germany). The images were captured with the software
ZEN (Zeiss, Oberkochen, Germany). As control, a suspension of
Lumogen® F Red 305 was administered.
3. Results
3.1. Preparation of GT-coated zein nanoparticles
The ﬁrst approach was to optimize the coating process of zein na-
noparticles. The inﬂuence of the GT-to-zein ratio on the physico-che-
mical properties of nanoparticles was evaluated (Table 1). As expected,
by increasing the GT-to-zein ratio, the mean size and the negative zeta
potential of the resulting nanoparticles increased. Under the
experimental conditions tested, all the nanoparticle formulations dis-
played homogeneous characteristics with a PDI below 0.2. All the na-
noparticles displayed negative surface charges, however, formulations
presenting the GT coating showed slightly more negative surface
charges than “naked” nanoparticles.
Fig. 1 shows TEM photographs of bare zein nanoparticles and zein
nanoparticles coated with GT at a GT-to-zein ratio of 5% (GT-NPZ2).
These nanocarriers displayed spherical shape and similar sizes to those
obtained by photon correlation spectroscopy. Interestingly, coated na-
noparticles showed a clear corona that was missing in uncoated zein
nanoparticles. The thickness of this coating layer, covering the surface
Table 1
Inﬂuence of the GT-to-zein ratio (expressed in percentage) on the physico-
chemical properties of the resulting nanoparticles. Data expressed as
mean ± SD (n=3).
Formulation GT-to-zein ratio
(%)
Size (nm) PDI Zeta Potential
(mV)
NPZ 0 235 ± 3 0.120 ± 0.014 −35 ± 4
GT-NPZ1 2.5 258 ± 2 0.091 ± 0.033 −45 ± 2
GT-NPZ2 5.0 271 ± 1 0.151 ± 0.016 −45 ± 3
GT-NPZ3 10 345 ± 8 0.182 ± 0.078 −55 ± 5
Fig. 1. Tomography electron microscopy of (A) “naked” zein nanoparticles
(NPZ) and (B) GT-coated nanoparticles (GTZ-NP).
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of zein nanoparticles, was estimated to be between 15 and 20 nm.
3.2. Multiple particle tracking (MPT) in mucus
The inﬂuence of the GT-to-zein ratio used for the preparation of
nanoparticles on the diﬀusion through porcine intestinal mucus was
assessed by the MPT technique (Table 2). GT-coated nanoparticles at a
GT-to-zein ratios of 2.5% (GT-NPZ1) and 5%, (GT-NPZ2) displayed
higher ability to diﬀuse through the mucus than “naked” nanoparticles
(NPZ). These bare NPZ particles showed a similar capacity to diﬀuse in
mucus to that of the poly(anhydride) nanoparticles (PA-NP). The<
Deﬀ>of GT-NP 2.5% (GT-NPZ1) was 2.2-fold higher than NPZ, while
the<Deﬀ>of GT-NP 5% (GT-NPZ2) was 24-fold higher than bare
zein nanoparticles. However, when the GT-to-zein ratio was increased
up to 10% (GT-NPZ3), the ability of the nanoparticles to diﬀuse through
the mucus signiﬁcantly decrease, being even slower than uncoated
nanoparticles and quite similar to PLGA-NP. In fact, GT-NPZ3 displayed
an important tendency to form aggregates with mucus.
3.3. Gastro-intestinal transit studies with 99mTc-nanoparticles
Fig. 2 shows the comparison of the gastro-intestinal transit data of
nanoparticles (radiolabeling with 99mTc) when administered by the oral
route to laboratory animals. In all cases, 2 h post-administration, na-
noparticles were localized in the stomach and the small intestine. Na-
noparticles coated with GT appeared to transit faster through the
gastro-intestinal tract than uncoated nanoparticles, as evidenced by
more intense signal in the small intestine than in the stomach. The
images in Fig. 2 show the intensity of the radioactivity in the stomach to
be higher for NPZ than for GT-NPZ1 (data not shown) and GT-NPZ2.
Surprisingly, GT-NPZ3 showed a signiﬁcantly lower intensity of the
radioactivity in the small intestine than GT-NPZ1 and GT-NPZ2. No
activity was observed in the liver or the lungs indicating a lack of any
measurable systemic availability of the oral administered particles.
3.4. Biodistribution studies with ﬂuorescently labeled nanoparticles
Fig. 3 shows ﬂuorescence microscopy images of ileum samples from
animals treated with Lumogen® F Red-labelled nanoparticles. Control
formulation (an aqueous suspension of the ﬂuorescent marker) was
visualized as large aggregates in the lumen or in contact with the ex-
ternal mucus layer (data not shown). Bare nanoparticles displayed a
localisation mainly restricted to the mucus layer protecting the epi-
thelium in the ileum (Fig. 3A and B). Conversely, for nanoparticles
containing GT as coating material appeared capable of reaching the
epithelium and interacting more widely with the intestinal cells
(Fig. 3C–H). This interaction was higher for GT-NPZ2 than for GT-NPZ1
and GT-NPZ3.
4. Discussion
The objective of this work was to explore the eﬀect of the coating of
zein nanoparticles with a hydrophilic conjugate (based on the binding
of thiamine to Gantrez® AN) on the mucoadhesive/mucus-penetrating
properties of the resulting nanocarriers. When zein nanoparticles were
coated with the GT conjugate, particle size increased as GT content
increased (Table 1). This increasing in the size of coated nanoparticles
was attributed to the formation of a polymer layer around the surface of
zein nanoparticles (Fig. 1). As a consequence, for zein nanoparticles
coated at a GT content of 5%, the mean particle size was ca. 11–15%
higher than for uncoated ones. Additionally, the coatings increased the
negative zeta potential compared to the bare nanoparticles. The in-
cremental increases in surface negative charges were directly related to
the presence of the conjugate on the surface of the nanoparticles. In-
deed, the binding of thiamine to the polymer backbone (through the
reaction and opening of the anhydride groups) would yield carboxylic
acids susceptible of ionization (Inchaurraga et al., 2019). During the
coating process, the hydrophobic portions of GT conjugate would in-
teract with the hydrophobic areas of zein nanoparticles, whereas the
hydrophilic thiamine groups and the carboxylic acids would remain
oriented through the external layer of the nanocarriers in contact with
the dispersant aqueous medium. This model concurs with Rouzes and
co-workers, who proposed a similar mechanism to explain the dis-
position of an amphiphilic dextran derivative when adsorbed on poly
(lactic acid) nanoparticles (Rouzes et al., 2000).
In order to study the capability of zein-based nanoparticles to dif-
fuse through a mucus layer in vitro, we used the multiple particle
tracking technique and intestinal pig mucus. In this study the diﬀerent
nanoparticles tested displayed negative zeta potentials and mean sizes
Table 2
Diﬀusion behavior of the diﬀerent formulations tested. Data expressed as
mean ± SD (n= 3). D°: diﬀusion coeﬃcient in water; <Deﬀ> : diﬀusion
coeﬃcient in mucus; ratio %<Deﬀ>/D°: relative eﬃciency of particles dif-
fusion; R: ratio between the %<Deﬀ>/D° for the diﬀerent formulations
tested and the %<Deﬀ>/D° value for NPZ; PLGA-NP: PLGA nanoparticles;
PA-NP: poly(anhydride) nanoparticles; NPZ: “naked” zein nanoparticles; GT-
NPZ1: GT-coated zein nanoparticles at a GT-to-zein ratio of 2.5%; GT-NPZ2:
GT-coated zein nanoparticles at a GT-to-zein ratio of 5%; GT-NPZ3: GT-coated
zein nanoparticles at a GT-to-zein ratio of 10%.






PLGA-NP 27.91 0.013 (±0.008) 0.0005 0.06
PA-NP 20.71 0.00167 (± 0.096) 0.0081 0.91
NPZ 19.12 0.00171 (± 0.034) 0.0089 1.00
GT-NPZ1 17.42 0.00376 (± 0.095) 0.0216 2.42
GT-NPZ2 16.58 0.04129 (± 1.639) 0.2490 27.98
GT-NPZ3 13.03 0.00030 (± 0.006) 0.0023 0.26
Fig. 2. Volume rendered fused SPECT-CT images from representative animals
2 h after administration of 99mTc-labelled NP by oral gavage. NPZ: “naked”
nanoparticles; GT-NPZ2: Gantrez® AN-thiamine-coated zein nanoparticles at a
GT/zein ratio of 5%; GT-NPZ3: Gantrez® AN -thiamine-coated zein nano-
particles at a GT/zein ratio of 10%.
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ranging from 160 nm (for control PLGA nanoparticles) till 350 nm (for
GT-NPZ3). MPT studies revealed that the coating of zein nanoparticles
with the Gantrez® AN-thiamine conjugate clearly modiﬁed their diﬀu-
sion in intestinal pig mucus (Table 2). This is in line with previous
observations describing that the capability of nanoparticles to pass
through a network of intestinal mucus is highly dependent on the
particle surface chemistry (Suk et al., 2011; Yildiz et al., 2015). PLGA
nanoparticles, as expected, displayed a very poor capability to diﬀuse
through the mucus. This ﬁnding aligns with previous works suggesting
that the hydrophobic surface characteristics of PLGA nanoparticles
would facilitate their interaction and binding with the hydrophobic
domains of the mucin chains (Mert et al., 2012; Mura et al., 2011). For
zein nanoparticles, their diﬀusivity in the mucus was found to be higher
than for PLGA nanoparticles and similar to that of poly(anhydride)
nanoparticles (Table 2), that have been deﬁned as mucoadhesive na-
nocarriers (Arbós et al., 2003, 2002; Yoncheva et al., 2005). Interest-
ingly, when zein nanoparticles were coated with GT (up to a GT-to-
protein ratio of 5%), the diﬀusion of the resulting nanocarriers through
mucus increased, and was very notable for GT-NPZ2 with a diﬀusion
coeﬃcient about 28-times higher than for bare nanoparticles.
When nanoparticles were coated with a GT-to-zein ratio of 10%
(GT-NPZ3), their diﬀusivity in intestinal mucus diminished some 6-fold
lower than that observed for bare zein nanoparticles. These nano-
particles displayed a tendency to form aggregates when mixed with
mucus. Even when expressing mucus diﬀusion relative to that in water
(i.e. normalizing for diﬀerences in particle size) the GT-NPZ3 particle
were less eﬃcient at permeating the mucus than NPZ (Table 2). This
behavior could be associated with a highly dense GT coating in GT-
NPZ3 that would result in a less ﬂexible coating with entanglements
between the poly(anhydride) chains that would facilitate their inter-
action with components of mucus layer. This phenomenon has been
previously reported with others polymers used as coating materials (Lee
et al., 2000; Inchaurraga et al., 2015).
The gastrointestinal-transit studies with radiolabelled nanoparticles
revealed that, 2 h post-administration, nanoparticles with the lowest in
vitro diﬀusivity (e.g., NPZ and GT-NPZ3) were mainly localized in the
stomach mucosa. This fact was particularly intense for GT-NPZ3
(Fig. 2). Conversely, the radioactivity associated to GT-NPZ2 was ob-
served (in a vast majority) in the small intestine of animals. In addition,
in vivo studies with the ﬂuorescently labelled nanoparticles
Fig. 3. Fluorescence microscopic visualisation of nanoparticles containing GT (GT-NPZ1, GT-NPZ2 and GT-NPZ3) and control ones (NPZ) in a longitudinal section of
the ileum of rats 2 h post administration. A and B: NPZ; C and D: GT-NPZ1; E and F: GT-NPZ2; G and H: GT-NPZ3.
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corroborated the mucoadhesive properties of NPZ (Fig. 3A and B), as
well as the mucus-permeating capabilities of GT coated nanoparticles
(Fig. 3C–F). Another important aspect to highlight is that the coating of
zein nanoparticles with GT produces nanocarriers capable of entering
rapidly in the small intestine, with a low residence time within the
stomach. This behavior has been previously observed for pegylated
nanoparticles (Inchaurraga et al., 2015) and might be an indication that
the “slippery” nanocarriers also oﬀer “targeting” properties for the
small intestine.
5. Conclusion
In summary, zein nanoparticles were coated with a Gantrez® AN-
thiamine conjugate to yield a continuous and homogeneous corona of
about 30 nm thickness. At GT-to-zein ratios up to 5%, the resulting
nanoparticles displayed an improved diﬀusion in intestinal mucus,
transforming the mucoadhesive properties of bare nanoparticles into
mucus-permeating characteristics. In addition, a good concordance
between in vitro MPT studies and in vivo results has been found.
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